000			03152cam a2200349 a 4500
003			EG-GiCUC
005			20250223031719.0
008			170502s2016 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.23.M.Sc.2016.As.C
100	0		_aAsmaa Magdy Saad Awaad
245	1	2	_aA clinicoepidemiological retrospective study of cases of uterine sarcoma who presented to radiotherapy department in NCI Cairo university in the period from jan 2000-Dec 2012 / _cAsmaa Magdy Saad Awaad ; Supervised Kamal Elghamrawy , Mervat Elnaggar , Shrewif Abdelfattah
246	1	5	_aدراسة اكلينيكية لحالات سرطان الانسجه الرخوه بالرحم التى تم علاجها بالمعهد القومى للأورام فى الفترة ما بين عام 2000الى عام 2012
260			_aCairo : _bAsmaa Magdy Saad Awaad , _c2016
300			_a175 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Oncology - Clinical
520			_aUterine sarcomas are rare tumors that account for approximately 1% of female genital tract malignancies and 3% to 7% of uterine cancers. To study the prevalence, stage and treatment results of uterine sarcoma in cases presented to national cancer institute-Cairo university during the period from 2000 to 2012 and to propose the recommendations for the value of combined modality therapy as standard of care for our patients. Retrospective study of 85 patients presented to national cancer institute from January 2000 to December 2012 with uterine sarcoma who underwent surgery then received Radiation therapy with or without brachytherapy or Radiation therapy with chemotherapy including radiation therapy details, type of chemotherapy, overall treatment period, and site of primary disease. Patients with metastatic disease, or no pathological confirmation were excluded The most frequently encountered pathology was malignant mixed mullarian tumour accounting for 40%. Patients most frequently presented with stage III disease. The most dominant site of metastasis on follow up was lung. The most frequently used treatment modality was surgery in combination with RT (52.9%), while 41.2% of the studied patients underwent surgery alone, 25.9 % recieved Brachytherapy after EBRT and 5.9% of patients underwent surgery followed by EBRT and chemotherapy. Of the evaluated patients, 70.3% achieved complete remission (no local recurrence). Addition of RT to surgery in treatment of patients with uterine sarcoma improved Local control, overall and disease-free survival with a highly statistically significant differences P value<0.001
530			_aIssued also as CD
653		4	_aRadiotherapy
653		4	_aRetrospective
653		4	_aUterine sarcoma
700	0		_aKamal Elghamrawy , _eSupervisor
700	0		_aMervat Elnaggar , _eSupervisor
700	0		_aShrewif Abdelfattah , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c60741 _d60741